From: A new nucleosomic-based model to identify and diagnose SSc-ILD
SSc (n = 67) | SSc-ILD (n = 31) | |
---|---|---|
Age, years | 56 ± 12 | 60 ± 13 |
Gender (M/F) | 17/50 | 6/25 |
BMI, kg/m2 | 25 ± 4 | 25 ± 4 |
Smokers (NS/FS/S) (%) | 48/28/24 | 55/28/17 |
Paq-year | 15 ± 17 | 6.9 ± 8.4 |
CRP | 1.7 (0.7-5.1) | 2.4 (1.1-6.1) |
FEV1 post-BD, % pred | 98 ± 22 | 88 ± 23* |
FVC post-BD, % pred | 104 ± 20 | 90 ± 22** |
FEV1/FVC post-BD, % pred | 78 ± 10 | 81 ± 8 |
TLC, % pred | 101 ± 15 | 85 ± 19*** |
TLCo % pred | 71 ± 20 | 56 ± 16** |
KCO % pred | 79 ± 19 | 74 ± 14 |
HRT extent (% lung) | / | 5 (5-25) |
IT, immunosupressive therapy (%) | 14 | 38 |
OCS, oral cortico steroide (%) | 24 | 28 |
Prednisolone equivalent (mg) | 5 (5-5) | 10 (5-10) |
GI tract score, none/mild/severe (%)1 | 36/62/2 | 16/80/4 |
Disease duration (year) | 6.93 ± 8.47 | 5.55 ± 5.87 |
Rodnan skin score | 2 (0-5)° | 2 (0-4)° |
limited SSc/lcSSc/dSSc/sine scleroderma (%) | 38/59/6.3/4.8 | 41/41/14/0 |
Musculoskeletal involvement (%) | 22 | 21 |
Renal crisis (%) | 6.8 | 0 |
Cardiac involvement (%) | 2 | 37 |